NTLA insider trading
NasdaqGM HealthcareIntellia Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Company website: www.intelliatx.com
NTLA insider activity at a glance
FilingIQ tracks 512 insider transactions for NTLA in filings since May 11, 2016. The most recent transaction is dated Aug 21, 2026.
Across the full history, 12 open-market purchases
and 285 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on NTLA insider trades is 54.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest NTLA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding NTLA
Politicians who have traded NTLA
Frequently asked
- How many insider trades does FilingIQ track for NTLA?
- FilingIQ tracks 512 Form 4 insider transactions for NTLA (Intellia Therapeutics, Inc.), covering filings from May 11, 2016 onwards. 3 of those are dated within the last 90 days.
- Are NTLA insiders net buyers or net sellers?
- Across the full Form 4 history for NTLA, 12 transactions (2%) were open-market purchases and 285 (56%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NTLA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is NTLA in?
- Intellia Therapeutics, Inc. (NTLA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.52B.
Methodology & sources
Every NTLA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.